Table 2.
Number of patients | Odds ratio [95% CI] | p-Value | |
---|---|---|---|
Baseline | |||
Age (per 10-year higher age) | 88 | 2.50 [1.46; 4.26] | < 0.001 |
Sex (women vs men) | 88 | 2.73 [0.95; 7.90] | 0.063 |
BMI (≥ 25 vs 20–25 kg/m2) | 88 | 0.74 [0.27; 2.06] | 0.566 |
GH (per 1-μg/L lower level) | 88 | 1.02 [0.98; 1.05] | 0.361 |
IGF-1 (per 50% lower level ULN) | 88 | 1.22 [0.94; 1.58] | 0.132 |
TV (per 100-mm3 smaller size) | 88 | 1.02 [0.99; 1.05] | 0.125 |
Week 12 | |||
GH (per 1-μg/L lower level) | 84 | 11.61 [3.12; 43.27] | < 0.001 |
IGF-1 (per 50% lower level ULN) | 85 | 4.70 [2.05; 10.81] | < 0.001 |
TV (per 100-mm3 smaller size) | 85 | 1.04 [0.99; 1.08] | 0.091 |
Change-from-baseline to week 12 | |||
GH (per 10% increase) | 84 | 0.78 [0.62; 0.98] | 0.030 |
IGF-1 (per 10% increase) | 85 | 0.58 [0.42; 0.81] | 0.001 |
TV (per 10% reduction) | 85 | 1.29 [0.91; 1.83] | 0.160 |
Factors in bold are statistically significant. Data are based on the number of patients with available data for each factor at each timepoint, and with p-values from Chi squared tests